Vanda Pharmaceuticals · 1 day ago
Sr. Finance Analyst
Vanda Pharmaceuticals is seeking a Sr. Finance Analyst who will perform general accounting and finance functions. The role involves ensuring accurate compilation, analysis, and reporting of financial data, assisting with Sarbanes-Oxley compliance, and providing business planning and analytical support.
BiopharmaBiotechnologyHealth Care
Responsibilities
Complete the month-end close process for specific line function - G&A and corporate activities
Complete the quarterly budgeting and forecasting process for specific line function
Assist with SEC reporting (annual 10-K, quarterly 10-Q and other periodic filings)
Ensures compliance with US GAAP and provides support for SOX testing and the annual audit process
Research technical accounting and reporting topics
Assist with ad-hoc projects supporting the Director of Finance and Controller
Qualification
Required
Minimum 2 years corporate finance and/or public auditing experience
BA/BS business/accounting/finance or other applicable business discipline
Strong understanding of US GAAP, SOX 404 compliance and internal controls
Expert proficiency with excel
Preferred
CPA with public accounting experience preferred with a Big 4 accounting firm
Life Sciences a plus
Benefits
Health insurance
Unlimited paid time off
Parental leave
A 401k matching program
Other benefits
Company
Vanda Pharmaceuticals
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies.
H1B Sponsorship
Vanda Pharmaceuticals has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (5)
2024 (7)
2023 (4)
2022 (1)
2021 (7)
2020 (1)
Funding
Current Stage
Public CompanyTotal Funding
$72.5M2014-10-29Post Ipo Equity· $54M
2006-04-12IPO
2004-10-01Series B· $18.5M
Leadership Team
Recent News
2026-01-06
2026-01-05
2026-01-03
Company data provided by crunchbase